|
1
|
O'Brien D, Jacob AG, Qualman SJ and
Chandler DS: Advances in pediatric rhabdomyosarcoma
characterization and disease model development. Histol Histopathol.
27:13–22. 2012.
|
|
2
|
Ognjanovic S, Linabery AM, Charbonneau B
and Ross JA: Trends in childhood rhabdomyosarcoma incidence and
survival in the United States, 1975–2005. Cancer. 115:4218–4226.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Geltzeiler M, Li G, Abraham J and Keller
C: The case for primary salivary rhabdomyosarcoma. Front Oncol.
5:742015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kashi VP, Hatley ME and Galindo RL:
Probing for a deeper understanding of rhabdomyosarcoma: Insights
from complementary model systems. Nat Rev Cancer. 15:426–439. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parham DM and Ellison DA:
Rhabdomyosarcomas in adults and children: an update. Arch Pathol
Lab Med. 130:1454–1465. 2006.PubMed/NCBI
|
|
6
|
Malempati S and Hawkins DS:
Rhabdomyosarcoma: Review of the Children's Oncology Group (COG)
Soft-Tissue Sarcoma Committee experience and rationale for current
COG studies. Pediatr Blood Cancer. 59:5–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kashima K, Watanabe M, Sato Y, Hata J,
Ishii N and Aoki Y: Inhibition of metastasis of rhabdomyosarcoma by
a novel neutralizing antibody to CXC chemokine receptor-4. Cancer
Sci. 105:1343–1350. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kokoris MS and Black ME: Characterization
of herpes simplex virus type 1 thymidine kinase mutants engineered
for improved ganciclovir or acyclovir activity. Protein Sci.
11:2267–2272. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nicholas TW, Read SB, Burrows FJ and Kruse
CA: Suicide gene therapy with Herpes simplex virus thymidine kinase
and ganciclovir is enhanced with connexins to improve gap junctions
and bystander effects. Histol Histopathol. 18:495–507.
2003.PubMed/NCBI
|
|
10
|
Andrade-Rozental AF, Rozental R,
Hopperstad MG, Wu JK, Vrionis FD and Spray DC: Gap junctions: The
'kiss of death' and the 'kiss of life'. Brain Res Brain Res Rev.
32:308–315. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peiris TH and Oviedo NJ: Gap junction
proteins: Master regulators of the planarian stem cell response to
tissue maintenance and injury. Biochim Biophys Acta. 1828:109–117.
2013. View Article : Google Scholar
|
|
12
|
Nielsen MS, Axelsen LN, Sorgen PL, Verma
V, Delmar M and Holstein-Rathlou NH: Gap junctions. Compr Physiol.
2:1981–2035. 2012.
|
|
13
|
Czyż J, Irmer U, Schulz G, Mindermann A
and Hülser DF: Gap-junctional coupling measured by flow cytometry.
Exp Cell Res. 255:40–46. 2000. View Article : Google Scholar
|
|
14
|
Di Ianni M, Di Florio S, Venditti G,
Falzetti F, Mannoni P, Martelli MF and Tabilio A: T lymphocyte
transduction with herpes simplex virus-thymidine kinase (HSV-tk)
gene: Comparison of four different infection protocols. J
Hematother Stem Cell Res. 8:645–652. 1999. View Article : Google Scholar
|
|
15
|
Mesnil M and Yamasaki H: Bystander effect
in herpes simplex virus-thymidine kinase/ganciclovir cancer gene
therapy: Role of gap-junctional intercellular communication. Cancer
Res. 60:3989–3999. 2000.PubMed/NCBI
|
|
16
|
You Y: Targets in Gene Therapy. InTech.
2011, http://dx.doi.org/10.5772/1012.
|
|
17
|
Neschadim A, Wang JC, Lavie A and Medin
JA: Bystander killing of malignant cells via the delivery of
engineered thymidine-active deoxycytidine kinase for suicide gene
therapy of cancer. Cancer Gene Ther. 19:320–327. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Veldwijk MR, Berlinghoff S, Laufs S,
Hengge UR, Zeller WJ, Wenz F and Fruehauf S: Suicide gene therapy
of sarcoma cell lines using recombinant adeno-associated virus 2
vectors. Cancer Gene Ther. 11:577–584. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wildner O, Morris JC, Vahanian NN, Ford H
Jr, Ramsey WJ and Blaese RM: Adenoviral vectors capable of
replication improve the efficacy of HSVtk/GCV suicide gene therapy
of cancer. Gene Ther. 6:57–62. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tseng JC, Zanzonico PB, Levin B, Finn R,
Larson SM and Meruelo D: Tumor-specific in vivo transfection with
HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis
for prodrug ganciclovir activation and PET. J Nucl Med.
47:1136–1143. 2006.PubMed/NCBI
|
|
21
|
Lin Z, Zhang Z, Han Y, Naus CC, Yu KR and
Holtzer H: Functional expression of gap junction gene Cx43 and the
myogenic differentiation of rhabdomyosarcoma cells. Sci China B.
38:305–312. 1995.PubMed/NCBI
|
|
22
|
Mesnil M: Connexins and cancer. Biol Cell.
94:493–500. 2002. View Article : Google Scholar
|
|
23
|
Garcia-Rodríguez L, Pérez-Torras S, Carrió
M, Cascante A, García-Ribas I, Mazo A and Fillat C: Connexin-26 is
a key factor mediating gemcitabine bystander effect. Mol Cancer
Ther. 10:505–517. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sanson M, Marcaud V, Robin E, Valéry C,
Sturtz F and Zalc B: Connexin 43-mediated bystander effect in two
rat glioma cell models. Cancer Gene Ther. 9:149–155. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tanaka M, Fraizer GC, De La Cerda J,
Cristiano RJ, Liebert M and Grossman HB: Connexin 26 enhances the
bystander effect in HSVtk/GCV gene therapy for human bladder cancer
by adenovirus/PLL/DNA gene delivery. Gene Ther. 8:139–148. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ciurea ME, Georgescu AM, Purcaru SO,
Artene SA, Emami GH, Boldeanu MV, Tache DE and Dricu A: Cancer stem
cells: Biological functions and therapeutically targeting. Int J
Mol Sci. 15:8169–8185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
CYTOVENE® Product Monograph.
http://www.rochecanada.com/en/products/pharmaceuticals/consumerinformation/cytovene.html.
|
|
28
|
van Dillen IJ, Mulder NH, Vaalburg W, de
Vries EFJ and Hospers GAP: Influence of the bystander effect on
HSV-tk/GCV gene therapy. A review Curr Gene Ther. 2:307–322. 2002.
View Article : Google Scholar
|
